Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav ® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jazz Pharmaceuticals announced positive results from two Phase 4 trials of Xywav, a low-sodium oxybate, for narcolepsy. The XYLO switch study demonstrated that switching from high-sodium oxybate to Xywav resulted in clinically meaningful reductions in blood pressure, a key comorbidity risk for narcolepsy patients, while the DUET trial showed improvements in daytime sleepiness with higher Xywav dosages (9-12 grams). These findings support Xywav's cardiovascular safety profile and efficacy in managing narcolepsy symptoms, potentially driving increased adoption of the low-sodium alternative.

Analysis

Jazz Pharmaceuticals has presented compelling Phase 4 clinical data for Xywav, its low-sodium oxybate, significantly bolstering its therapeutic profile for narcolepsy. The XYLO switch study (n=43) demonstrated a clinically meaningful and statistically significant mean reduction of 4.1 mmHg in 24-hour ambulatory systolic blood pressure (SBP) (P=0.0019) upon switching from high-sodium oxybates to Xywav, a critical benefit for narcolepsy patients prone to cardiovascular comorbidities. This was complemented by significant improvements in daytime SBP (-5.1 mmHg, P=0.0003) and seated SBP (-9.2 mmHg, P<0.0001). Furthermore, an interim analysis from the DUET trial (n=24) suggested enhanced efficacy in managing excessive daytime sleepiness with Xywav dosages between 9-12 grams per night, exceeding the current 6-9 gram recommendation, while maintaining a consistent safety profile characterized by mild to moderate treatment-emergent adverse events. These findings reinforce Xywav's key differentiating factor—a 92% reduction in sodium load compared to traditional oxybates—which underpins its FDA-recognized clinical superiority for cardiovascular safety and its Orphan Drug Exclusivity. The robust data supports Xywav's potential for increased adoption and market share within Jazz's neuroscience portfolio, particularly as a preferred long-term treatment for chronic conditions like narcolepsy and idiopathic hypersomnia, despite its Schedule III classification and REMS program requirements.

Key Decisions for Investors

• Consider the strong clinical data from the XYLO and DUET trials as supportive of Xywav's continued market penetration and potential for optimized dosing, which could enhance Jazz Pharmaceuticals' revenue from its neuroscience franchise.
• Assess the competitive advantage Xywav gains from its significantly lower sodium content and demonstrated blood pressure reduction benefits, particularly in a patient population with heightened cardiovascular risks, as a key driver for displacing older, high-sodium oxybate therapies.
• Monitor ongoing physician and patient adoption of Xywav, as these positive trial results are likely to be leveraged in marketing efforts, while remaining cognizant of the REMS program requirements and the established safety profile associated with oxybate treatments.